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 TYPE OF INVESTIGATION: Treatment                                                                               
QUESTION                                                                                                                                   
In infants (>35 weeks gestation with BW >2000 g) born through meconium-stained amniotic 
fluid with respiratory distress (defined by Downe score >4 with SpO2 <90% on room air) does 
nasal continuous positive airway pressure (NCPAP) compared with 5-10 L/min hood oxygen 
reduce the risk of the need for mechanical ventilation (MV) in the first 7 days of life?                                                                                                                                                                                                                            
METHODS                                                                                                                            
Design: Multicenter, open-label, randomized controlled trial                                                                
Allocation: Parallel-group at a 1:1 ratio of randomly alternated computer generated blocks of 2 
or 4, stratified by center                                                                                                                                              
Blinding: Open-label, unblinded (clinicians).                                                                                                 
Follow up period: Infants were followed until discharge from the hospital.                                                                 
Setting: Three tertiary care neonatal intensive care units in India.                                                            
Patients                                                                                                                                            
Inclusion criteria. Infants >35 weeks gestation, >2000 g birth weight, born through meconium-
stained fluid, admitted to the neonatal intensive care unit (NICU) within the first 24 hours of life, 
with respiratory distress using Downe scoring (a tool for categorizing the degree of respiratory 
distress) (1), of >4 with capillary oxygen saturation <90% on room air) and chest radiograph 
indicative of meconium aspiration syndrome.                                  
Exclusion criteria. Severe asphyxia (Apgar score of <3 at 5 minutes and cord pH <7.00), 
intubation at admission, pneumothorax or air leak on chest radiograph upon admission, major 
congenital malformations.                                                                                                
Intervention                                                                                                                                    
Eligible neonates were randomized at study enrollment to either bubble NCPAP or hood oxygen. 
Arterial blood gas and chest radiograph were obtained prior to randomization. NCPAP pressure 
and fraction of inspired oxygen (FiO2) were titrated to a target saturation of 90%-95%. 
Participants were weaned off NCPAP once saturations were persistently >90%, FIO2 
requirement was <25%, and respiratory distress had resolved.  
Outcomes                                                                                                                                       
The primary outcome was the need for MV, defined by: 1. NCPAP failure (SpO2 levels <90% 
on NCPAP pressure of 6 cm of water and 100% FIO2), 2. hood oxygen failure (SpO2 <90% for 
greater than 15 minutes on 100% FIO2), 3. persistent shock requiring inotropes >10 ug/kg/min, 
4. elevated partial pressure of carbon dioxide (greater than 60 mm Hg) with pH less than 7.20, or 
5. hemodynamic compromise with new-onset pneumothorax in the first 7 days of life. Secondary 
outcomes included the need for surfactant, culture positive sepsis, pulmonary hypertension, 
death, pneumothorax, duration of oxygen and length of hospital stay.                                                   
Statistical Analysis and Sample size                                                                                    
Results were analyzed using intention-to-treat for all participants. A sample size of 66 infants per 
group was needed to achieve 80% power with an alpha error of 0.05 and detect a reduction of 
treatment failure from 30% (rate of failure in existing data on hood oxygen) to 10% in the 
NCPAP group. Study group comparisons of discrete variables were performed using logistic 
regression. Study group comparisons of continuous variables were performed using log 
transformation. For center comparisons, linear regression was performed.                                                           
Patient follow-up: Written informed consent was obtained via infant families within an hour of 
NICU admission. 91% of those eligible were included in the study for randomization. The other 
9% were excluded due to severe birth asphyxia (n=9), poor respiratory effort requiring intubation 
at birth (n=3), and consent refusal (n=2). 100% of the randomized patients were included in the 
primary and secondary analyses.                                                                                                                  
MAIN RESULT                                                                                                                              
Overall cohort: In total, 135 neonates were randomly assigned to the treatment group (67 to the 
NCPAP group and 68 to the standard treatment group). Mean birth weight was 2944 g, average 
gestation was 38.2 weeks, 41.5% male. Baseline characteristics between groups did not differ.  
Primary outcome                                                                                                                      
Treatment failure as defined by need for MV, occurred in 3% of the NCPAP group, and 25% of 
the hood oxygen group (odds ratio, 0.09; 95% confidence interval 0.02-0.43; p = 0.002). 17 of 
the 19 infants who failed hood oxygen were placed on NCPAP prior to MV and 15 were 
ultimately placed on MV. Four out of the 19 infants who failed hood oxygen required high 
frequency ventilation (HFV) for failed conventional MV. None of the infants in the NCPAP 
group required HFV. The number needed to treat was 4.5; for every five infants with MAS who 
received NCPAP instead of hood oxygen one infant would avoid MV.                                                         
Secondary outcomes                                                                                                                          
More infants in the hood oxygen group required surfactant, developed culture positive sepsis, 
and had a longer duration of oxygen requirement than in the NCPAP group. One infant in the 
hood oxygen group died from pulmonary hemorrhage. One infant in the NCPAP group 
developed a pneumothorax.                                                                                                            
STUDY CONCLUSION                                                                                                                 
Initiation of early NCPAP instead of hood oxygen in neonates with respiratory distress due to 
MAS decreases the risk of subsequent MV in the first seven days of life. For every five infants 
with respiratory distress due to MAS supported with NCPAP, one infant will be protected from 
subsequent MV.                                                                                                                 
COMMENTARY                                                                                                                  
Meconium aspiration syndrome (MAS) continues to be a significant source of respiratory failure 
in the neonatal population (2, 3). While mortality rates of MAS have decreased over the years, 
significant morbidity/mortality still exist, particularly from the need for MV (4). In fact, up to 
50% of neonates with MAS will need ventilator support (4) with associated costs of prolonged 
hospital stay, need for continued critical care, and other morbidities (5). In neonates requiring 
ventilation, short-term risks include air leak syndromes and pulmonary hemorrhage, while long-
term risks include prolonged respiratory compromise post-discharge, cerebral palsy and global 
developmental delay (5, 6).                                                                                                                                       
          While a large number of neonates with MAS will need respiratory support, the ideal 
ventilatory strategy remains unknown (7). Since lung mechanics are altered with significant 
atelectasis and obstruction in MAS, respiratory management has historically included hood 
oxygen without positive pressure to limit the risks of worsened air trapping and resultant air 
leaks (7). However, persistent high oxygen exposure is not benign and has been shown to worsen 
pulmonary arterial constriction in lambs as well as lead to increased neonatal risks of 
bronchopulmonary dysplasia, retinopathy of prematurity, and necrotizing enterocolitis (8, 9). As 
an alternative, NCPAP has been proposed for the prevention of MV as it provides positive 
pressure with reduced oxygen administration (4, 7). Known benefits of NCPAP include 
improved atelectasis, reduced air trapping, and decreased ventilation-perfusion mismatch for 
improved gas exchange, while slightly increasing the risk of pneumothorax compared to other 
modalities (4, 7).                                                                                   
            The NCPAP for MAS trial evaluated the feasibility of using early NCPAP for 
noninvasive respiratory support in the first week of life. Strengths of this study include a 
randomized, multisite design with mostly inborn infants, exclusion of infants with hypoxic 
respiratory failure, and sufficient power to detect differences between groups. The 3% failure 
rate in neonates randomized to the NCPAP treatment group vs. 25% in the hood oxygen group 
was greater than that predicted by chance alone (odds ratio, 0.09; 95% CI, 0.02-0.43; P=0.002).  
           Although the study was powered to show a difference in rates of treatment failure, the 
resource-poor setting may have generated some generalizability limitations. For instance, the 
Downes (1) score has good reproducibility across multiple settings, but it is not routinely used in 
neonatal intensive care units in the US. Additionally, while inhaled nitric oxide is considered 
standard therapy in the US for severe pulmonary hypertension, it was not used in this cohort 
which may suggest either a differing patient population or a resource-limited setting. Likewise, 
given limited resource availability of higher-level support, specific treatment failure criteria may 
have been more generous. Lastly, the potential for variability both in the clinician discretion to 
place neonates on either NCPAP or MV following hood oxygen failure and specific protocol 
differences on comorbid condition management may have been partially due to resource 
restrictions.                                                    
           This was a well-designed and implemented study with low to moderate risk of bias that 
provides a good argument for the use of early NCPAP support in MAS. The study provides an 
intervention with relative applicability for most neonatal intensive care units in the US. The 
intervention of NCPAP is feasible, with relatively easy accessibility and low cost. Overall, the 
study presents a compelling argument for trialing early NCPAP in near-term and term infants 
with respiratory failure to prevent MV in the first seven days of life.                                                                                                                                                           
EBM LESSON: PERMUTED BLOCKED RANDOMIZATION                                                                                                
         One of the most important components in a clinical trial is randomization because it 
reduces sample bias - a participant’s or investigator’s ability to preemptively enroll into a desired 
treatment group.  As such, it allows a relatively nonbiased valid outcome assessment by 
optimizing the distribution of both known and unknown participant characteristics and 
prognostic variables between groups.  One specific type of allocation randomization, “permuted 
blocked randomization”, ensures participants are assigned to either treatment or control groups 
based on a constant predetermined ratio of allocation, such as 1:1 in this study, and alternating 
between a permutated block size of 2:4 patients (10, 11). In this case, two patients are enrolled 
into alternating groups followed by the next four patients who are enrolled in variable order into 
alternating groups. The process is repeated until the total enrollment is achieved, ensuring an 
equal number of subjects in each group when enrollment is complete. Investigators use 
permutation of block size to make it more difficult to predict the block size and thus, predict or 
influence patient group. By randomly assigning new participants in block groups with equal 
probability, blocked randomization helps limit selection bias, avoid group imbalance, and 
maintain a valid assessment (10, 11).  
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